TY - JOUR
T1 - Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass
AU - Rubattu, Speranza
AU - Sciarretta, Sebastiano
AU - Ciavarella, Giuseppino Massimo
AU - Venturelli, Vanessa
AU - De Paolis, Paola
AU - Tocci, Giuliano
AU - De Biase, Luciano
AU - Ferrucci, Andrea
AU - Volpe, Massimo
PY - 2007/4
Y1 - 2007/4
N2 - OBJECTIVES: The metabolic syndrome (MS) is associated with left ventricular hypertrophy (LVH). Previous evidence has shown that LVH is favoured by low levels of atrial natriuretic peptide (ANP), independently from blood pressure (BP), in hypertension. Although levels of natriuretic peptides are known to be lower in obesity, plasma ANP levels have not yet been assessed in MS. We aimed to assess the ANP levels and their relationship with left ventricular mass (LVM) in patients affected by MS. METHODS: One hundred and twenty-eight essential hypertensive patients were included in the study: 51 with MS and 77 without MS. Clinical, echocardiographical and biochemical parameters, and levels of both N-terminal (NT)-proANP and alphaANP were assessed. RESULTS: Hypertensive patients affected by MS had higher LVM and increased frequency of LVH. NT-proANP levels were significantly lower in MS, independent of waist circumference (WC). Log(NT-proANP) levels were significantly inversely related to left ventricular mass index (LVMI) (β = -0.360, P <0.001) and LVM/height (β = -0.370, P <0.001) in the whole hypertensive population by multiple linear regression analysis. The relationship of log(NT-proANP) with LVM was more enhanced in patients with MS. CONCLUSIONS: The present study demonstrates that levels of NT-proANP are significantly reduced in hypertensive patients affected by MS, and they are significantly inversely related to the increased LVM observed in these patients. Our findings, while supporting previous experimental and clinical evidence of the antihypertrophic role of ANP in hypertension, may help to identify one of the possible mechanisms directly underlying LVH in MS.
AB - OBJECTIVES: The metabolic syndrome (MS) is associated with left ventricular hypertrophy (LVH). Previous evidence has shown that LVH is favoured by low levels of atrial natriuretic peptide (ANP), independently from blood pressure (BP), in hypertension. Although levels of natriuretic peptides are known to be lower in obesity, plasma ANP levels have not yet been assessed in MS. We aimed to assess the ANP levels and their relationship with left ventricular mass (LVM) in patients affected by MS. METHODS: One hundred and twenty-eight essential hypertensive patients were included in the study: 51 with MS and 77 without MS. Clinical, echocardiographical and biochemical parameters, and levels of both N-terminal (NT)-proANP and alphaANP were assessed. RESULTS: Hypertensive patients affected by MS had higher LVM and increased frequency of LVH. NT-proANP levels were significantly lower in MS, independent of waist circumference (WC). Log(NT-proANP) levels were significantly inversely related to left ventricular mass index (LVMI) (β = -0.360, P <0.001) and LVM/height (β = -0.370, P <0.001) in the whole hypertensive population by multiple linear regression analysis. The relationship of log(NT-proANP) with LVM was more enhanced in patients with MS. CONCLUSIONS: The present study demonstrates that levels of NT-proANP are significantly reduced in hypertensive patients affected by MS, and they are significantly inversely related to the increased LVM observed in these patients. Our findings, while supporting previous experimental and clinical evidence of the antihypertrophic role of ANP in hypertension, may help to identify one of the possible mechanisms directly underlying LVH in MS.
KW - Essential hypertension
KW - Left ventricular mass
KW - Metabolic syndrome
KW - Natriuretic peptides
UR - http://www.scopus.com/inward/record.url?scp=33947099984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947099984&partnerID=8YFLogxK
U2 - 10.1097/HJH.0b013e32803cae3c
DO - 10.1097/HJH.0b013e32803cae3c
M3 - Article
C2 - 17351376
AN - SCOPUS:33947099984
VL - 25
SP - 833
EP - 839
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 4
ER -